We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.20 | 8.20 | 8.98 | 498 | 08:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.53 | 16.59M |
TIDMOBD
RNS Number : 0433L
Oxford BioDynamics PLC
03 September 2019
3 September 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Life Sciences Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 10,000 Ordinary Shares of 1 pence each at a price of 90p per share.
Following this transaction, Vulpes Life Sciences Fund is interested in 11,751,455 Ordinary Shares, representing approximately 12.70% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Stephen Diggle ------------------------------- -------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------- a) Position/status Director/PDMR ------------------------------- -------------------------------------- b) Initial notification/ Initial notification Amendment ------------------------------- -------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------- a) Name Oxford BioDynamics Plc ------------------------------- -------------------------------------- b) LEI 2138005Y1TK258O5U928 ------------------------------- -------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------- a) Description of the Ordinary Shares of 1 pence each financial instrument, ISIN: GB00BD5H8572 type of instrument Identification code ------------------------------- -------------------------------------- b) Nature of the transaction Acquisition of ordinary shares ------------------------------- -------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 0.90 10,000 ---------- ------------------------------- -------------------------------------- d) Aggregated information Price Volume - Aggregated volume 0.90 10,000 - Price ------- ------------------------------- -------------------------------------- e) Dates of the transactions 2 September 2019 ------------------------------- -------------------------------------- f) Place of the transaction Outside a trading venue ------------------------------- --------------------------------------
For further details please contact:
Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO +44 (0)1865 518910 Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield +44 (0)20 7408 4090 FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHLJMPTMBIMMAL
(END) Dow Jones Newswires
September 03, 2019 04:47 ET (08:47 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions